News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma and Genentech Expand Oncology Collaboration

BOULDER, Colo., April 7 /PRNewswire-FirstCall/ -- Array BioPharma (Nasdaq: ARRY) today announced an expansion of a collaboration agreement with Genentech, Inc. (NYSE: DNA) to develop small molecule drugs against an additional protein target in the field of oncology.

The original collaboration, which began in January 2004, was formed to advance two of Array's proprietary oncology programs into clinical development. Under the expanded agreement, Array will receive additional research funding, as well as research and development milestone payments and product royalties based on the success of the new program.

"We believe Genentech's expansion of our research collaboration further validates Array's leadership position in cancer research," said Robert E. Conway, Chief Executive Officer, Array BioPharma. "This collaboration leverages Array's proprietary small molecule drug discovery expertise with Genentech's cancer expertise, with the goal of creating products to address one the world's largest unmet medical needs and market opportunities."

Details of the Transaction

Under the terms of this expanded agreement, Genentech and Array will collaborate on the discovery of clinical candidates directed against a cancer target, generated by Genentech. Genentech will have the sole responsibility for clinical development and commercialization of the resulting products.

About Array BioPharma

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of orally active drugs to address significant unmet medical needs. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes several small molecule drug candidates that are designed to regulate targets in therapeutically important biologic pathways. In addition, leading pharmaceutical and biotechnology companies access our drug discovery technologies and expertise through collaborations to design, create, optimize and evaluate drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Array Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed in our annual report filed on form 10-K for the year ended June 30, 2004, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties for their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet drug objectives, including clinical trials, tied to milestones and royalties, and our ability to attract and retain experienced scientists and management. We are providing this information as of April 7, 2005. We undertake no duty to update any forward- looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

SOURCE Array BioPharma
04/07/2005
CONTACT: Tricia Haugeto of Array BioPharma, +1-303-386-1193, thaugeto@arraybiopharma.com
Web site: http://www.arraybiopharma.com
(ARRY DNA)